Navigation Links
Resolve Initiates Phase 2 Clinical Study in SLE
Date:7/16/2014

SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).

Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients.  The study will be conducted at multiple sites in the U.S., and will investigate four dose levels, with multiple doses being administered over one month.  The study is designed to establish biological proof-of-concept for RSLV-132.

RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG.  The goal of the therapy is to reduce the burden of circulating RNA-containing immune complexes which are thought to be the most proximal trigger of the systemic inflammation characteristic of SLE.  By eliminating the RNA cargo contained in circulating immune complexes the therapy is designed to prevent chronic activation of nucleic acid sensing toll like receptors (e.g. TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade.  Additional therapeutic benefit is thought to result from dampening B-cell activation, as well as mitigation of the direct tissue damage caused by immune complex deposition in key organs, such as the kidney and brain.

"We are thrilled to move RSLV-132 one step closer to the large number of SLE patients that are not well controlled with current therapy" commented James Posada, chief executive officer of Resolve Therapeutics.

About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of its platform of targeted nuclease therapeutics.  In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus and other autoimmune diseases resulting from aberrant nucleic acid deposition.  Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital.  For more information on the company please visit us at:  http://www.resolvebio.com

Contact:

James Posada, Ph.D., MBA
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 876-4057
jp@resolvebio.com

Logo - http://photos.prnewswire.com/prnh/20140715/127341


'/>"/>
SOURCE Resolve Therapeutics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
2. New nanomedicine resolves inflammation, promotes tissue healing
3. WMIS Supports Experts, Commits to Resolve Beta Amyloid Issues with CMS
4. BioFit Helps Lab Specifiers Resolve to Improve Worker Safety and Productivity in 2013 through Ergonomic Seating Use
5. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth
8. EquitiesIQ Initiates Coverage of Alliqua, Inc.
9. OxThera Initiates Clinical Trial in Primary Hyperoxaluria
10. Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
11. Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 This report analyzes the worldwide ... Acid Based (Humic, Amino, & Fulvic), Extract Based, and Others. ... Crop Types: Ornamental & Turf, Row Crops, and Others. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... finalists in the World Technology Awards. uBiome is one of just six company ... all categories. , In addition to uBiome, companies nominated as finalists in this ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):